Committed to sharing our science

Committed to sharing our science

381 results available

Understanding the Use of Noninvasive Ventilation in the Treatment of Amyotrophic Lateral Sclerosis: Results of an International Physician Survey

Poster, 27th International Symposium on ALS/MND
Dublin, Ireland
Heiman-Patterson T, Andrews JA, Cudkowicz M, de Carvalho M, Genge A, Hardiman O, Jackson C, Kulke S, Lechtzin N, Mitsumoto H, Rudnicki SA, Silani V, van den Berg LH
December 2016
Machine Learning Model for the Prediction of Slow Vital Capacity

Poster, 27th International Symposium on ALS/MND
Dublin, Ireland
December 2016
Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial

The Lancet
Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams Jr KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V.
December 2016

Highly Selective Inhibition of Myosin Motors Provides the Basis of Potential Therapeutic Application

Proceedings of the National Academy of Sciences (PNAS)
Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K.
November 22, 2016

CK-2127107, a Selective Activator of the Fast Skeletal Muscle Troponin Complex, for the Potential Treatment of Spinal Muscular Atrophy

Poster, 2016 Annual SMA Conference
Orlando, FL
Rudnicki SA, Andrews JA, Malik FI, Wolff AA, Day JW
June 2016

« Previous 1 … 53 54 55 56 57 … 77 Next »

Home

Mission

Science

Our Medicine

Company

Responsibility

Careers

Updated Privacy Policy

Cookie Policy

Terms of Use

Patent Notices

CYTOKINETICS^® and the C logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Cytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical and scientific community through peer-reviewed journals and medical forums. Our scientific publications (e.g., manuscripts, posters and/or oral presentations that contain data from Cytokinetics-sponsored studies, have Cytokinetics authors, or for which Cytokinetics provides writing and/or editorial assistance) are generally intended for health care professionals.

If you have specific questions or require additional information, please contact Cytokinetics Medical Information at [email protected].

Note: All content provided as is and per applicable permissions; some links provided below redirect to third-party websites that may require a subscription to access publications.

I understand

Cytokinetics scientists and collaborators are committed to high scientific and ethical research standards and are dedicated to better understanding and advancing the science of muscle biology and diseases of muscle dysfunction. Our Investigator-Initiated Research program is intended for scientists and health care professionals.

If you have specific questions or require additional information, please contact the Cytokinetics Investigator-Initiated Research team at [email protected] (clinical submissions) or [email protected] (non-clinical or pre-clinical submissions).

Note: All content provided as is and per applicable permissions; some links provided below redirect to third-party websites that may require a subscription to access publications.

I understand

We’re proud to announce that the U.S. Food and Drug Administration has approved MYQORZO™ (aficamten)!

Read our press release

Please see Full Prescribing Information, including BOXED WARNING here.